Background: Acute thrombotic syndromes lead to atherosclerotic plaque rupture
| INTRODUCTION
Platelet-extracellular matrix and platelet-platelet adhesions are central to the formation of thrombi. MMP-13 is up-regulated in inflammation, and is elevated in the atherosclerotic plaque, contributing to its vulnerability. 1 It is also implicated in the progression and remodelling of cerebral tissue in stroke. 2 Plaque rupture releases MMP-13
into the local environment where it has direct access to plasma proteins, blood cells, and platelets. Following injury to the blood vessel wall, specific platelet receptors mediate platelet-collagen and platelet-platelet interactions. GPIbα binds to immobilized von Willebrand factor (VWF) in the vessel wall, initiating platelet capture, 3 and glycoprotein (GP)VI binds directly to collagen and activates platelets.
Integrin α2β1 stabilises the early stages of the platelet-collagen interaction, and integrin αIIbβ3 supports platelet-platelet interactions mediated by fibrinogen and VWF. [4] [5] [6] [7] MMP-2 and -9 have previously been shown to bind to platelet receptors and/or to modulate platelet function. [8] [9] [10] [11] [12] [13] Here, we hypothesized that MMP-13 may also interact directly with platelet receptors GPVI, integrin α2β1, or the platelet adhesive integrin αIIbβ3
to modulate platelet adhesion, aggregation and thrombus formation.
Our work identifies potential roles for MMP-13 in modulating the recruitment or activation of platelets in thrombotic pathologies.
| METHODS

| MMP-13 expression, purification and activation
ProMMP-13 and its MMP-13 catalytic (CAT, 249-451) domain were expressed, purified, activated, and dialysed as previously described. [14] [15] [16] The structurally homologous but catalytically inactive proMMP-13(E204A) was a kind gift from Dr. R. Visse (Kennedy Institute of Rheumatology Division, Imperial College London, London, UK). GST-Hemopexin (HPX) domain (264-471) was expressed in E. coli using the pGEX-2T expression vector, the forward primer TCCGCGTGGATCCCTCTATGGTCCAGGAGATGAA and the reverse primer GCAA-ATTCCATTTTGTGGTGTTGAAGAATTCAT, which contain BamHI and EcoRI restriction sites respectively, as previously described. 16 
| Washed platelet preparation and platelet adhesion assays
Plates were coated with 10 μg/ml MMP-13 variants in Tris buffered saline (TBS) for 1 h at 24°C. Plates were then blocked with 5% BSA in TBS for 20 minutes at 24°C and washed with TBS prior to the addition of washed platelets. Platelets were purified and adhesion assays conducted as previously described. 17, 18 Glanzmann thrombasthenic blood was kindly provided by RGDS (Arg-Gly-Asp-Ser) and cyclic RGD (H-Cys-Arg-Gly-Asp-PhePro-Ala-Ser-Ser-Cys-OH) were purchased from Bachem, Weil am Rhein, Germany. The fibrinogen-derived peptide, Lys-Gln-AlaGly-Asp-Val (KQAGDV), was purchased from Innovagen, Sweden.
Inhibitory antibodies/compounds were used at 10 μM (6F1, 10B12, 1C3, 2D4, cRGD, GR144053, KQAGDV) or 100 μmol L −1 (fibrinogen and RGDS).
| Flow cytometry
In activation experiments, whole blood diluted 1:4 with Hepes buffered saline (HBS) was mixed for 10 minutes at 24°C with an equal volume of 10 μg/ml mouse anti P-Selectin (Abcam, Cambs, UK) and the following agonists 2 mmol L −1 proMMP-13(E204A) or MMP-13, 100 μg/ ml CRP-XL, 100 μg/ml HORM ® equine collagen I fibers (Takeda, Linz, Austria), thrombin activating peptide (TRAP; 500 μmol L 
| Solid phase adhesion assays
Recombinant human αIIbβ3 and GPVI monomer were obtained from R&D Systems (Abingdon, Oxford, UK 
| Aggregometry
Washed platelet aggregation was performed using a Chrono-Log turbidimetric aggregometer (Labmedics, Abingdon on Thames, UK 
| Electrophoresis and Western blotting
Protein samples in reducing sample buffer were boiled for 5 minutes and applied to 4-12% NuPage Gels and separated by electrophoresis using the Xcell SureLock system (Invitrogen, Paisley, UK) under reducing conditions. Proteins were then transferred on to nitrocellulose membrane (Millipore, Bedford, UK) at 40 V overnight at 4°C using a Mini Protean II system (Bio-Rad, Hemel Hempstead, UK).
Following transfer, the PVDF was blocked (5% nonfat dry powdered 
| Whole blood perfusion experiments
Whole blood was pre-incubated with either carrier (TBS) or 80 nmol L −1 MMP-13 for 1 h prior to perfusion over 10 μg/mL type I fibrous collagen as previously described. 17, 25 Where indicated, slides
were coated with MMP-13(E204A) alone as a (negative) control.
| RE SULTS
Adhesion assays were performed in the presence of 2 mmol L −1 EDTA or Mg 2+ to ablate or support integrin-mediated adhesion.
Platelet adhesion to MMP-13 preparations was significantly reduced, but not abolished, by EDTA, suggesting both integrindependent and -independent contributions, whereas EDTA fully abolished binding to the collagen-binding integrin-specific peptide GFOGER ( Figure 1A ).
Platelet pre-incubation with the αIIbβ3 antagonists, GR144053, cRGD, and RGDS, and with anti-GPVI scFv 10B12 and 1C3, all caused a substantial and significant reduction (P < .01) in platelet adhesion to proMMP-13 ( Figure 1A) , with residual adhesion being observed in the presence of EDTA remaining above negative control levels (nonspecific substrates). This may indicate cooperative binding to αIIbβ3 F I G U R E 2 Competition, GPVI and Glanzmann platelet binding assays. (A) MMP-13(E204A) and either 10B12 or GR144053 were used to obtain IC 50 values for the inhibition of washed platelet adhesion to 10 μg/ml coated fibrinogen (i, iii) or CRP (ii, iv), respectively. (v) Adhesion of MMP-13(E204A) to recombinant human GPVI monomer and dimer. Plates were coated with 10 μg/ml GPVI or BSA as a negative control. MMP-13(E204A) at a concentration of 83 nM was allowed to adhere for 1 h at room temperature, then detected using an antibody directed at the MMP-13 linker region, as described in Methods. Data represent mean A 450 ± SE of three experiments. (B) Platelets from a healthy donor (red bars) and from a Glanzmann thombasthenic individual (orange bars) were allowed to adhere to MMP-13, fibrinogen and CRP-XL coated plates. Where appropriate, platelets were pre-incubated with anti-GPVI (1C3), or αIIbβ3 antagonists as described for Figure 1 . Data represent mean A 405 ± SE of duplicate readings for one experiment due to the rarity of the Glanzmann donor and GPVI. Interaction between MMP-13 and integrin α2β1 was less prominent, since blocking antibody 6F1 had just a small effect, and was not studied further. Platelet pre-incubation with the fibrinogenderived peptide, KQAGDV, had no effect on platelet adhesion, indicating that MMP-13 binds αIIbβ3 closer to the primary RGD-binding site. Soluble fibrinogen also did not block platelet adhesion to MMP-13, in line with the need for platelet activation for soluble fibrinogen binding to αIIbβ3 to occur, whereas immobilized fibrinogen is already competent to bind. The GPVI-specific scFv, 1C3, does not target the collagen-binding site at the apex of GPVI, unlike 10B12, and was unable to inhibit the adhesion of washed platelets to CRP ( Figure 1B ).
1C3 binding requires both GPVI Ig domains and is thought to reduce platelet activation by inhibiting receptor clustering; its epitope includes isoleucine 148, 21,23 located in strand E on the opposite face of D2 to the crystal structure dimerization interface located in strand G. 24 An indifferent control, the anti-HLA-A2 scFv, 2D4, was inactive in these experiments. In subsequent experiments, only low platelet binding was observed to isolated CAT and HPX domains of MMP-13 in comparison with the intact protein ( Figure 1C ), indicating that neither domain alone governs the interaction between the MMP and platelets, and supporting the possibility that two sites on MMP-13 cooperate to bind αIIbβ3 and GPVI.
Competition assays in which washed platelets were pre-incubated with increasing amounts of the catalytically-dead MMP- (results not shown). Adhesion of αIIbβ3-null Glanzmann platelets to MMP-13, however, was markedly reduced ( Figure 2B[i] ). Blockade of αIIbβ3 on healthy platelets resulted in the same adhesion level as seen for αIIbβ3-null platelets. As expected, binding of Glanzmann platelets to fibrinogen was abolished ( Figure 2B [ii]) and to CRP was unaffected ( Figure 2B [iii]). Our results indicate that, whilst MMP-13 appears able to bind to αIIbβ3 on the platelet surface, recombinant αIIbβ3 used here cannot reproduce this effect.
Whilst it was able to cleave the recombinant αIIbβ3 β-chain and GPVI in solution, as well as fibrinogen α and β chains ( Figure 3A) , MMP-13(E204A) significantly reduced platelet aggregation to a series of agonists, and for the mid-range dose of each, analyzed using two-way anova, the inhibitory effect of MMP-13 was significant (P < .01). Prominent amongst these stimuli were: CRP-XL, ionophore A23187, and bovine fibrillar collagen I, for which it was easier to establish mid-range doses than for thrombin and equine fibrillar collagen. A summary of results is shown in Figure 4A Figure 5B ). This would suggest that in solution, the polymeric CRP-XL is a more potent ligand than MMP-13, and that the interaction of MMP-13 with αIIbβ3 predominates over that with GPVI.
We investigated the influence of MMP-13 or MMP-13(E204A) on platelet adhesion and activation in flowing blood in vitro, using fibrillar collagen I coatings and a shear rate of 1000 s −1. Pre-incubation of whole blood with MMP-13 resulted in significantly reduced platelet surface coverage (P < .05), mean thrombus height (P < .01), and ZV 50 (P < .05), using one-way anova and Holm multiple comparison test; Figure 6A (i-iii). ZV 50 is the height within a Z-stack at which thrombus volume = 50% and describes the activation state of adhered platelets in flowing human blood. 25 Data obtained using pre-incubations with MMP-13(E204A) reached significance only for mean thrombus height (P < .05, Figure 6A [ii]). MMP-13(E204A)- 
| D ISCUSS I ON
We have previously shown that degradation by MMP-13 has the potential to modulate platelet adhesion to collagen. 17 MMPs are zymogens; proteolysis is required to expose their catalytic site.
Here we show that surprisingly, all forms of MMP-13, pro-and active wild type enzyme as well as their catalytically inactive mutant counterparts, were able to support a high level of platelet adhesion under static conditions. This adhesion was inhibited by the anti-GPVI scFvs 10B12 and 1C3 suggesting that the relatively large MMP-13 occludes the sites of both 10B12 and 1C3 binding on the receptor. MMP-13 was also able to bind strongly to the GPVI dimer.
Although GPVI dimerization increases upon platelet activation, dimeric GPVI is also present on resting platelets and is required for their initial interaction with exposed collagen. 26 Crystallography of the proMMP-13 structure in complex with pro-domain peptides revealed a dimeric form as an HPX-mediated dimer like some other metalloproteinases, although in this study, 27 Until now, the role of MMP-13 in atherothrombosis has been considered to be restricted to collagen proteolysis and remodelling, rendering plaque more friable and prone to rupture. 1 However, MMPs are now emerging as important mediators of platelet function. 32, 33 MMPs -1 and -2 are released from activated platelets where they colocalize with integrins at the sites of platelet-platelet interaction. 10, 34 Active MMP-1 and -2 can stimulate platelet function, suggesting receptor engagement and proteolysis. 34, 35 MMPs in atherosclerotic lesions, released from the injured vessel wall itself or from platelets and monocytes, and that can also interact with platelets, are likely to interfere with the progression of plaque rupture, subsequent thrombosis and its associated pathologies including stroke, reperfusion injury, and hemorrhagic transformation. Indeed, these processes are associated with an upregulation of MMP activity. 2, 31, 36 In mice, MMP-13 is the key mediator of collagen degradation in atheroma and confers instability onto the vulnerability plaque cap. [37] [38] [39] Disruption of the blood brain barrier (BBB) by MMPs is associated with hemorrhagic transformation following ischemic stroke, 36, 40, 41 whilst MMPs -9 and -13 are implicated in the early pathology of stroke progression, and plasma MMP-13 levels correlate with lesion volume. 2, 31 In addition, the platelet collagen receptor GPVI has been identified in models of models of reperfusion injury, 42 is associated with increased risk of stroke development, and is also seen after ischemic stroke. 43 Here we demonstrate that MMP-13 can exert an antithrombotic effect; inhibiting platelet aggregation and thrombus formation in flowing whole blood. It may be that this metalloproteinase has multiple roles in the pathology of ischemic stroke; firstly by undermining the stability of the fibrous cap of atheroma and so promoting its rupture, then modulating the BBB to increase bleeding risk, and finally acting on platelets to impair the aggregatory interactions, by antagonising GPVI and αIIbβ3 which would normally protect against bleeding. MMP-13 would appear therefore to modulate the architecture around sites of infarction to increase both risk of stroke and its hemorrhagic complications. The effect of MMP-13 will depend upon its local level and the exposure of MMP-13-binding matrix components and warrants further investigation.
